Courtesy of Dr. Agustín Vecchia. Surgery is the treatment of choice for patients with symptomatic aortic insufficiency and/or ventricular dilatation or decreased ventricular function. The broad implementation of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis, the emergence of new devices, and the experience acquired by operators have brought this treatment to off-label indications such<a href="https://solaci.org/en/2016/12/13/tavr-in-pure-aortic-insufficiency-yes-or-no/" title="Read more" >...</a>
Transapical and Transaortic TAVR: Valid Alternatives to the Transfemoral
Courtesy of Dr. Carlos Fava. The femoral approach has been the gold standard for the transcatheter aortic valve replacement procedure (TAVR); however, it is anatomically unsuitable for an important number of patients, and these require a different approach. At present, there is little evidence in support of the transapical or transaortic access sites as<a href="https://solaci.org/en/2016/12/02/transapical-and-transaortic-tavr-valid-alternatives-to-the-transfemoral/" title="Read more" >...</a>
Valve Thrombosis After TAVR: Larger-Diameter Valves and No Warfarin as Predictors
There are limited data on the incidence, clinical implications, and predisposing factors of valve thrombosis in patients who underwent transcatheter aortic valve replacement (TAVR). This study aimed at determining such information through multislice computed tomography (CT). This trial included 460 consecutive patients who underwent TAVR with a balloon-expandable Edwards Sapien XT or Sapien 3 (Edwards Lifesciences,<a href="https://solaci.org/en/2016/11/13/valve-thrombosis-after-tavr-larger-diameter-valves-and-no-warfarin-as-predictors/" title="Read more" >...</a>
TAVR in Pure Aortic Regurgitation Is Associated with Lower Mortality Rates
This study summarizes all available evidence on transcatheter aortic valve replacement (TAVR) for the treatment of native pure aortic regurgitation. Surgical replacement is the standard of care for pure aortic regurgitation. However, there are many reports of cases and small studies in which high-risk patients with pure aortic regurgitation were treated with TAVR. <a href="https://solaci.org/en/2016/11/01/tavr-in-pure-aortic-regurgitation-is-associated-with-lower-mortality-rates/" title="Read more" >...</a>
Cerebral Protection in TAVR: Studies Presented at London Valves
SENTINEL One of the new devices assessed at London Valves was Sentinel, which is made up of two independent filters. The larger filter is deployed in the brachiocephalic trunk, and the smaller filter is deployed in the left common carotid artery. The study included 22 patients and the device was deployed successfully in 20 of them<a href="https://solaci.org/en/2016/10/20/cerebral-protection-in-tavr-studies-presented-at-london-valves/" title="Read more" >...</a>
Stroke Predictors in TAVR: CoreValve vs. Sapien
A comprehensive analyzis of cerebrovascular events in major randomized controlled studies on transcatheter aortic valve replacement (TAVR) has shown some interesting data on both risks and timing of stroke in this setting. The study carried out by Dr. Neal Kleiman, reviewed data on stroke and stroke predictors among 3,687 patients included in the CoreValve<a href="https://solaci.org/en/2016/09/21/stroke-predictors-in-tavr-corevalve-vs-sapien/" title="Read more" >...</a>
Aortic Angulation: Impact on the Success of TAVR
Original Title: Aortic Angulation Attenuates Procedural Success Following Self-Expandable But Not Balloon-Expandable TAVR. Reference: Abramowitz Y et al. JACC Cardiovasc Imaging. 2016 Jul 8. [Epub ahead of print]. The angulation degree between aorta and heart can make precise valve implantation challenging, especially extreme angulation, such as a horizontal aortic root. As obvious as it<a href="https://solaci.org/en/2016/07/22/aortic-angulation-impact-on-the-success-of-tavr/" title="Read more" >...</a>
Transcatheter Mitral Valve Replacement: A New Arrow in the Bow
Original Title: Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease With Severe Mitral Annular Calcification: Results From the First Multicenter Global Registry Reference: J Am Coll Cardiol Intv. 2016;9(13):1361-1371. doi:10.1016/j.jcin.2016.04.022 Gentileza del Dr. Agustín Vecchia. The risk underlying the surgical approach to mitral valve replacement in patients with severe mitral annular calcification is high. A<a href="https://solaci.org/en/2016/07/15/transcatheter-mitral-valve-replacement-a-new-arrow-in-the-bow/" title="Read more" >...</a>
Valve-in-Valve: High or Low Implantation for Better Outcomes?
Original Title: Transcatheter Replacement of Failed Bioprosthetic Valve. Large Multicenter Assessment of the Effect of Implantation Depth on Hemodynamics after Aortic Valve-in Valve. Reference: Matheus Simonato, et al. Circ. Cardiovasc. Interv 2016;9:e003651 Courtesy of Dr. Carlos Fava. At present, most patients undergoing surgical valve replacement receive a bioprosthetic valve, which lasts from 10 to<a href="https://solaci.org/en/2016/07/12/valve-in-valve-high-or-low-implantation-for-better-outcomes/" title="Read more" >...</a>
Medtronic’s New CoreValve Evolut R for TAVR
Original Title: Treatment of Symptomatic Severe Aortic Stenosis with a Novel Resheathable Supra-Annular Self-Expanding Transcatheter Aortic Valve System. Reference: Ganesh Manoharan et al. J Am Coll Cardiol Intv. 2015; 8(10):1359-1367. Courtesy of Dr. Agustín Vecchia. Despite the rapid growth and evolution of transcatheter aortic valve replacement devices (TAVR), vascular access complications, paravalvular leak, stroke<a href="https://solaci.org/en/2016/07/08/medtronics-new-corevalve-evolut-r-for-tavr/" title="Read more" >...</a>